TECHWIRE 30
(CIX: WRAL30)  1,126.59  up arrow+2.55  (0.23 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Apple)  111.78  down arrow-0.87  (-0.77 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: QUINTILES)  60.39  up arrow+1.01  (1.7 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: BASF SE)  85.15  down arrow-1.55  (-1.78 %)  Updated: 05:20 PM EST, Dec 19 2014
(NQ: BioCryst)  11.16  up arrow+0.08  (0.68 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: BioDelivery)  13.82  up arrow+0.76  (5.82 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: CEMP)  21.31  up arrow+0.8  (3.9 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cisco Systems)  27.77  up arrow+0.12  (0.43 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cree)  31.21  up arrow+0.31  (1 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: DARA)  0.88  up arrow+0.04  (4.3 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: EMC CORPORATION)  30.14  up arrow+0.19  (0.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Extreme Networks)  3.44  up arrow+0.09  (2.69 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: FB)  79.88  up arrow+1.48  (1.89 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: GLAXOSMITHKLINE)  43.35  up arrow+0.06  (0.14 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: GOOG)  516.35  up arrow+5.25  (1.03 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: IBM)  158.51  up arrow+0.83  (0.53 %)  Updated: 06:40 PM EST, Dec 19 2014
(NY: LH)  105.80  down arrow-0.64  (-0.6 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Lenovo Group)  26.38  up arrow+0.82  (3.21 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: MRK)  59.58  up arrow+0.6  (1.02 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Microsoft Corp)  47.66  up arrow+0.14  (0.29 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: NTAP)  42.94  up arrow+0.22  (0.52 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: NOVARTIS AG)  94.61  up arrow+0.04  (0.04 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Novozymes A/S)  43.11  down arrow-0.32  (-0.73 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: PFIZER)  31.94  down arrow-0.03  (-0.09 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Pozen)  8.17  up arrow+0.27  (3.42 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: RED HAT)  68.04  up arrow+6.54  (10.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: BBRY)  9.99  down arrow-0.08  (-0.79 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Salix)  117.20  down arrow-1.25  (-1.06 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: SQI)  14.97  down arrow-0.09  (-0.6 %)  Updated: 08:10 PM EST, Dec 19 2014

Posts tagged “GSK”

2:29 p.m. Tuesday

#WTWTrends for Tuesday: Jobs, GSK, Broadband and Connected Cars Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Tuesday, Dec. 16, 2014 as curated by @WRALTechWire.

Updated 11:25 a.m. Tuesday

Despite layoffs at GSK, raise a glass (at least) half full

Veteran journalist Jim Shamp sees upside and downside in the recently announced job cuts at GlaxoSmithKline. After all, he notes, cuts in the past as GSK evolved locally from Burrough Wellcome to Glaxo to Glaxo Wellcome and today have produced a harvest of new companies, new ideas, and products. "Yes, a shakeup like GSK's cutback announcement is shattering," he writes. "But these are smart, talented people who will get back on their feet and contribute greatly to North Carolina's life science future."

GSK Headquarters      GSK Headquarters

10:19 a.m. Monday

RTP drug firm launching clinical trial of possible Ebola treatment

Ebola RTP-based BioCryst Pharmaceuticals is launching a clinical trial of a potential treatment for Ebola with funding support from the U.S. government. Durham-based Chimerix and GSK also are involved in the Ebola battle.

Updated December 11

Backers pledge $390M for Ebola; side effects delay one trial

Ebola Even as backers pledged $390 million for Ebola vaccines, Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. It's not the vaccine being tested by GlaxoSmithKline.

Updated December 9

NC firms help lead Ebola fight but face multiple battles

Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.

GSK's Donna Altenpohl GSK's Donna Altenpohl

Updated December 9

North Carolina's role in fighting Ebola highlights conference in RTP

Ebola North Carolina's role in fighting the Ebola epidemic striking western Africa and a disease that is a global threat will be discussed Monday at a conference in Research Triangle Park.

Updated December 5

Ebola NC: Conference to focus on state's role, preparations in fighting outbreak

Ebola Government, health, private sector executives will gather at a conference focusing on the Ebola outbreak and North Carolina's involvement as well as preparations for a possible health crisis here.

Updated December 5

Premium Lock GSK cuts a 'severe blow' to RTP, says science blogger at forefront of layoff reports

Dr. Derek Lowe, a veteran pharmaceutical scientist and long-time Internet blogger, was among the first to report details of GSK's 20% job force reduction in RTP. Fed information from friends and contacts within the industry, he has written several insightful blogs about what's happening at the drug giant and across the pharmaceutical industry, particularly in R&D. And he tells WRAL TechWire that GSK's cuts are a "severe blow" to the Triangle.

December 4

#WTWTrends for Thursday: GSK, Orion, 12 Days of Broadband, and #Flu Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Thursday, Dec. 4, 2014 as curated by @WRALTechWire.

Updated December 3

GSK files notice confirming 'approximately 900' layoffs in Triangle

GlaxoSmithKline will lay off hundreds of research and development workers at its Research Triangle Park campus, the company said in an official notice to the state.

GSK's R&D facility in RTP  GSK's R&D facility in RTP

Updated December 3

Hundreds of GSK workers could end up at new RTP employer

GSK  Up to 450 employees of drug giant GlaxoSmithKline who face being laid off may find employment quickly at Parexel, a life science research firm with an office in RTP. GSK says it has signed a letter of intent to create a GSK-focused group within Parexel.

December 3

#WTWTrends: GSK jobs, HQRaleigh, startups, innovation grants, and Airbnb Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Wednesday, Dec. 3, 2014 as curated by @WRALTechWire.

December 3

GSK's full statement on layoffs: Cuts are 'strategic'

GSK  In a statement, GlaxoSmithKline explains the cutbacks being made in research and development at Research Triangle Park and other locations. "Our proposed changes to R&D will sharpen the focus in discovery and development and reduce funding in certain areas of the pipeline," the drug giant says.

Updated December 1

Drug giant GSK reportedly will lay off hundreds in US

GlaxoSmithKline is preparing to lay off hundreds of workers in the U.S., according to various media reports. A company spokesperson in RTP, where the company operates its North American headquarters, confirms that a reorganization is underway but won't comment on specifics.

GSK's R&D facility in RTP  GSK's R&D facility in RTP

Updated December 1

Premium Lock Lost amid layoff news: GSK's advance toward Ebola vaccine

The Ebola outbreak isn't generating big headlines in the U.S. these days, but forthcoming layoffs at GlaxoSmithKline are a hot topic. Unfortunately for GSK, the job cuts have overshadowed the company's progress in developing the first vaccine for the deadly Ebola.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

November 19

Premium Lock Survey shows corporate progress in embracing LGBT equality

A new survey from the Human Rights Campaign finds that a record number of companies, including seven in North Carolina, received perfect scores in corporate inclusion for lesbian, gay, bisexual and transgender employees. Bank of America, Blue Cross Blue Shield of NC and GlaxoSmithKline are among those receiving a "100" on the Corporate Equality Index.

Survey finds more LGBT equality in corporate America Survey finds more LGBT equality in corporate America

November 18

Premium Lock Uber regulation coming in NC?; IBM's $1.25B outsourcing deal; GSK Ebola vaccine update; FTC says TRUSTe deceived consumers; SAP to pay Oracle $359M

Bulldog In today's Bulldog wrapup of tech and life science news: A N.C. General Assembly committee is to discuss possible Uber regulations; IBM lands a $1.25 billion outsourcing deal with Lufthansa; GSK's Ebola vaccine is safe in early tests; the FTC settles complaint with TRUSTe; and SAP will pay Oracle $359 million to settle a long legal battle.

October 31

Premium Lock Longtime GSK exec Viehbacher ousted as Sanofi CEO

Chris Viehbacher Chris Viehbacher, a longtime GSK executive and triangle resident who lost out in the battle to become CEO of that job giant, has lost his job as CEO at French drugmaker Sanofi.

Updated October 24

Premium Lock GSK exec on Ebola vaccine trial: 'We only have one shot to get this right'

Ebola The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?

October 22

Premium Lock Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll